Trial Profile
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-146; KEYNOTE-526
- Sponsors Eisai Inc
- 05 Jan 2024 Results focusing on Characterization and Management of Adverse Reactions ,published in the Oncologist
- 06 Jan 2023 Updated results (data cutoff date August 18, 2020, n=108) analyzing long-term follow-up efficacy and safety data of included in the primary analysis patients with previously treated EC, published in the Journal of Clinical Oncology
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.